Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline ...

The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033 moving forward with ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

The Pasadena, Calif., biotechnology company, which uses RNA interference to develop treatments, said Monday it recorded a profit of $370.4 million, or $2.75 a share, during the fiscal second quarter, ...

Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating ...

Arrowhead Pharmaceuticals prepares for the 2025 commercial launch of plozasiran, bolstered by a $1.375B Sarepta deal, advancing pipeline, and ...

Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET. Company Participants. Vincent Anzalone - Vice President of Investor Relatio ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, ...

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, ...

Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to ...